S3-selection of Patients for Tki Treatment

Patients with advanced DTC who are refractory to I treatment have a life expectancy of 36 years and represent a group for whom there is a clear unmet medical need (1). Radioiodine refractory thyroid cancer is not common, with an estimated incidence of four cases per million population year (5% of patients with clinical thyroid cancer, 250 patients per year in France) (2,3). It occurs more frequently in older patients, in those with large metastases or with poorly differentiated thyroid cancer, and in those with high FDG uptake on PET scan (1, 4).